Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer

[1]  A. Khabir,et al.  Genetic Polymorphisms in the EGFR (R521K) and Estrogen Receptor (T594T) Genes, EGFR and ErbB-2 Protein Expression, and Breast Cancer Risk in Tunisia , 2009, Journal of biomedicine & biotechnology.

[2]  C. Marsit,et al.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. , 2009, Carcinogenesis.

[3]  J. Long,et al.  A Two-stage Case-Control Study of EGFR Polymorphisms and Breast Cancer Risk , 2009, Cancer Epidemiology Biomarkers & Prevention.

[4]  M. Páez de la Cadena,et al.  Absence of Activating Mutations in the EGFR Kinase Domain in Spanish Head and Neck Cancer Patients , 2007, Tumor Biology.

[5]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[6]  G. Tortora,et al.  Rational bases for the development of EGFR inhibitors for cancer treatment. , 2007, The international journal of biochemistry & cell biology.

[7]  Ziding Feng,et al.  Memorial Sloan-Kettering Cancer , 2006 .

[8]  W. Kuo,et al.  EGFR Intron 1 polymorphism in asian populations and its correlation with EGFR gene expression and amplification in breast tumour tissues , 2006, Cancer Biology & Therapy.

[9]  Y. Marie,et al.  Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma , 2006, Neurology.

[10]  L. O’Driscoll,et al.  Biomarkers and multiple drug resistance in breast cancer. , 2006, Current cancer drug targets.

[11]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yueping Shen,et al.  Joint Effects of the CYP1A1 MspI, ERα PvuII, and ERα XbaI Polymorphisms on the Risk of Breast Cancer: Results from a Population-Based Case-Control Study in Shanghai, China , 2006, Cancer Epidemiology Biomarkers & Prevention.

[13]  S. Groshen,et al.  Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. , 2005, Clinical colorectal cancer.

[14]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[15]  N. Dalay,et al.  Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. , 2004, Experimental and molecular pathology.

[16]  Jan F. Silverman,et al.  Molecular Evolutionary Patterns in Breast Cancer , 2003, Advances in anatomic pathology.

[17]  X. Shu,et al.  Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[19]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[20]  E. Cook,et al.  Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  D. Noh,et al.  Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. , 2002, Cancer letters.

[22]  S. Narod.  Modifiers of risk of hereditary breast and ovarian cancer , 2002, Nature Reviews Cancer.

[23]  R. Schiff,et al.  Estrogen receptor: current understanding of its activation and modulation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[25]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[26]  R. Lea,et al.  Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer , 2001, International journal of cancer.

[27]  R. Wooster,et al.  Breast cancer genetics: What we know and what we need , 2001, Nature Medicine.

[28]  I. Persson.  Estrogens in the causation of breast, endometrial and ovarian cancers — evidence and hypotheses from epidemiological findings , 2000, Journal of Steroid Biochemistry and Molecular Biology.

[29]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[30]  B. Weber,et al.  Low penetrance genes associated with increased risk for breast cancer. , 2000, European journal of cancer.

[31]  R. Houlston,et al.  Detecting low penetrance genes in cancer: the way ahead , 2000, Journal of medical genetics.

[32]  C. Campagnoli,et al.  HRT and breast cancer risk: a clue for interpreting the available data. , 1999, Maturitas.

[33]  B. Ponder,et al.  A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .

[34]  M. Fernö,et al.  Prognostic factors in breast cancer: a brief review. , 1998, Anticancer research.

[35]  C. Mathew,et al.  Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. , 1996, Cancer letters.

[36]  N. Roodi,et al.  Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. , 1995, Journal of the National Cancer Institute.

[37]  K. Heimdal,et al.  Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility , 1994, Human Genetics.

[38]  S. Lehrer,et al.  Oestrogen and progesterone receptor dissociation and family history of breast cancer , 1992, The Lancet.

[39]  L. Murphy,et al.  Characterization of estrogen receptor variant mRNAs from human breast cancers. , 1992, Molecular endocrinology.

[40]  W. Dupont,et al.  Genomic DNA analysis of the estrogen receptor gene in breast cancer , 1989, Breast Cancer Research and Treatment.

[41]  Y H Xu,et al.  Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells , 1985, Molecular and cellular biology.

[42]  I. Edelman,et al.  Mechanism of action of steroid hormones. , 1975, Journal of steroid biochemistry.

[43]  J. Dixon,et al.  ABC of breast diseases , 2012 .

[44]  S. Saxena,et al.  Changing trends in incidence of breast cancer: Indian scenario. , 2009, Indian journal of cancer.

[45]  I. Tentes,et al.  Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. , 2007, Neoplasma.

[46]  Zhong Wen-zhao,et al.  Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .

[47]  J. Chang-Claude.  Inherited genetic susceptibility to breast cancer. , 2001, IARC scientific publications.

[48]  H. Melhus,et al.  Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. , 2000, Carcinogenesis.

[49]  K McPherson,et al.  ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. , 2000, BMJ.

[50]  W D Dupont,et al.  Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. , 1992, Cancer research.

[51]  L. L. Engel,et al.  Mechanism of action of steroid hormones , 1961 .